Zhenkai Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhenkai Chen has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Kashif Rafiq Zahid
Department of Radiation Oncology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA
1 shared publicationLina Yang
Department of Laboratory Medicine, Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, Guangdong, P. R. China
1 shared publicationLiwen Jiang
Department of Pathology, Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, Guangdong, P. R. China
1 shared publicationQiyuan Huang
Center for Sleep and Circadian Medicine, The Affiliated Brain Hospital of Guangzhou Medical University, Guangdong, P. R. China
1 shared publicationRuiqi Su
Southern Medical University
1 shared publication- Tao Zeng
Department of Medical Laboratory, Affiliated Hospital of Guangdong Medical University, Zhanjiang, P. R. China
1 shared publication
Latest Publications
- Open Access
- 29 May 2025
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 40 (2) , 96-104
High Kin17 expression is correlated with metastasis and prognosis of esophageal squamous cell carcinoma
Background: Kin17 is critical in regulating the proliferation and metastasis of tumors in various malignancies. However, the relationship between Kin17 expression, clinicopathologic features, and esophageal squamous cell carcinoma (ESCC) prognosis remains unclear. Methods: The analysis of Kin17 messenger RNA (mRNA) expression involved the utilization of data from The Cancer Genome Atlas (TCGA) dataset through the platforms the University of ALabama at Birmingham CANcer data analysis portal (UALCAN) and the Gene Expression Omnibus (GEO). To determine the expression levels of Kin17 in tissues, immunohistochemistry was conducted. Using Pearson's chi-square test, the relationship between Kin17 expression and clinicopathological variables was evaluated. Cox proportional hazard models (both univariate and multivariate), receiver operating characteristic (ROC) curves, and Kaplan–Meier survival curves were used to analyze survival. Results: In both the TCGA and GEO datasets, the mRNA level of Kin17 was greater in tumor tissues when compared to tumor-adjacent tissues ( P < 0.001). Similarly, there was a significant expression of Kin17 ( P < 0.0001) in ESCC tissues. Elevated Kin17 expression correlated significantly with increased Ki-67 levels ( P < 0.001), advanced pathological tumor node metastasis stage ( P = 0.01), and positive lymph node metastasis ( P = 0.02). According to univariate and multivariate Cox models, high Kin17 expression was associated with poorer progression-free survival (PFS) (hazard ratio (HR): 1.990, 95% confidence interval (CI): (1.040–3.810)), and Kin17 was an independent prognostic variable for overall survival (OS) (HR: 2.321, 95% CI: (1.056–5.101)). ROC curve showed that the area under the curve for predicting PFS and OS using the combination of Kin17 and K-i67 was 0.7088 and 0.7031, respectively. High Kin17 expression was associated with unfavorable PFS (HR: 2.009, 95% CI: (1.059–3.811)) and OS (HR: 2.997, 95% CI: (1.488–6.040)). Conclusions: Kin17 is abundantly expressed in ESCC tissues and is potentially useful for prognostic evaluation and as a target for therapeutic interventions in ESCC.
- 29 May 2025
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 40 (2) , 96-104
Open AccessHigh Kin17 expression is correlated with metastasis and prognosis of esophageal squamous cell carcinoma
Background: Kin17 is critical in regulating the proliferation and metastasis of tumors in various malignancies. However, the relationship between Kin17 expression, clinicopathologic features, and esophageal squamous cell carcinoma (ESCC) prognosis remains unclear. Methods: The analysis of Kin17 messenger RNA (mRNA) expression involved the utilization of data from The Cancer Genome Atlas (TCGA) dataset through the platforms the University of ALabama at Birmingham CANcer data analysis portal (UALCAN) and the Gene Expression Omnibus (GEO). To determine the expression levels of Kin17 in tissues, immunohistochemistry was conducted. Using Pearson's chi-square test, the relationship between Kin17 expression and clinicopathological variables was evaluated. Cox proportional hazard models (both univariate and multivariate), receiver operating characteristic (ROC) curves, and Kaplan–Meier survival curves were used to analyze survival. Results: In both the TCGA and GEO datasets, the mRNA level of Kin17 was greater in tumor tissues when compared to tumor-adjacent tissues ( P < 0.001). Similarly, there was a significant expression of Kin17 ( P < 0.0001) in ESCC tissues. Elevated Kin17 expression correlated significantly with increased Ki-67 levels ( P < 0.001), advanced pathological tumor node metastasis stage ( P = 0.01), and positive lymph node metastasis ( P = 0.02). According to univariate and multivariate Cox models, high Kin17 expression was associated with poorer progression-free survival (PFS) (hazard ratio (HR): 1.990, 95% confidence interval (CI): (1.040–3.810)), and Kin17 was an independent prognostic variable for overall survival (OS) (HR: 2.321, 95% CI: (1.056–5.101)). ROC curve showed that the area under the curve for predicting PFS and OS using the combination of Kin17 and K-i67 was 0.7088 and 0.7031, respectively. High Kin17 expression was associated with unfavorable PFS (HR: 2.009, 95% CI: (1.059–3.811)) and OS (HR: 2.997, 95% CI: (1.488–6.040)). Conclusions: Kin17 is abundantly expressed in ESCC tissues and is potentially useful for prognostic evaluation and as a target for therapeutic interventions in ESCC.